Sepsis syndrome is the potentially lethal response to a systemic bacterial infection. A principal complication of sepsis is secondary lung infection, most notably nosocomial pneumonia, estimated to directly relate to as many as 15% of all hospital deaths. Macrophages play an essential role in the resolution phase of pulmonary infection. Recruitment of macrophages to the infected lung is regulated by a class of cytokines called p-chemokines, which mediate their chemotactic activity via binding to specific p-chemokine receptors. Work by us and others has shown that exposure of macrophages to bacterial IPS results in sustained downregulation of three p-chemokine receptors (CCR1, CCR2, and CCR5), markedly impairing the ability of affected cells to migrate in response to p-chemokine signals. These data raise the possibility that LPS- triggered defects in p-chemokine receptor expression interfere with normal macrophage trafficking in septic patients, and contribute to the immunocompromised state that permits secondary lung infection to flourish in these patients. The molecular mechanisms that mediate sustained downregulation of p-chemokine receptors in LPS-treated macrophages are not known. Also, the potential link between chemokine receptor dysregulation in sepsis patients and increased susceptibility to secondary infection has yet to be explored. Our long-term goal is to overcome mechanisms that subvert effective pulmonary defense in septic patients. The objectives of the current application are to identify the mechanisms and clinical consequences of macrophage p-chemokine receptor loss within the context of sepsis.
In Specific Aim 1, we will use a combination of biochemical, gene knockout, dominant-negative mutant, and RNAi techniques to test our working hypothesis that LPS-induced defects in p-chemokine receptor expression and function are mediated via activation of a Src family kinase and subsequent activation of the small GTPase, Rac, via its guanine nucleotide exchange factor, Vav.
In Specific Aim 2, we will test our working hypothesis that p-chemokine receptor expression and function are impaired in murine endotoxemia and in patients with sepsis, and that these receptor defects correlate with increased susceptibility to lung infections. The rationale that underlies the proposed research is that knowledge of the mechanisms and clinical consequences of macrophage B-chemokine receptor loss and/or dysfunction in sepsis will offer new targets for therapeutic intervention.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI059742-04
Application #
7548180
Study Section
Special Emphasis Panel (ZRG1-III (01))
Program Officer
Sawyer, Richard T
Project Start
2006-02-01
Project End
2011-01-31
Budget Start
2009-02-01
Budget End
2010-01-31
Support Year
4
Fiscal Year
2009
Total Cost
$275,048
Indirect Cost
Name
Feinstein Institute for Medical Research
Department
Type
DUNS #
110565913
City
Manhasset
State
NY
Country
United States
Zip Code
11030
Chatterjee, Prodyot K; Al-Abed, Yousef; Sherry, Barbara et al. (2009) Cholinergic agonists regulate JAK2/STAT3 signaling to suppress endothelial cell activation. Am J Physiol Cell Physiol 297:C1294-306
Winzeler, Elizabeth Ann (2008) Malaria research in the post-genomic era. Nature 455:751-6
Sherry, Barbara; Dai, Wei Wei; Lesser, Martin L et al. (2008) Dysregulated chemokine receptor expression and chemokine-mediated cell trafficking in pediatric patients with ESRD. Clin J Am Soc Nephrol 3:397-406